Dr. Thompson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-606-2044
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1982 - 1985- University of WashingtonResidency, Internal Medicine, 1979 - 1982
University of Alabama School of MedicineClass of 1979
Certifications & Licensure
WA State Medical License 1980 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Interleukin-2 in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 1996 Jan 01
- Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer Start of enrollment: 2013 Feb 15
Publications & Presentations
PubMed
- Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma.Jamie S K Takayesu, Upendra Parvathaneni, George E Laramore, Neil Panjwani, Jennifer Sillings
Cancer Reports. 2025-02-01 - Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events.Malek Shatila, Hao Chi Zhang, Anusha Shirwaikar Thomas, Antonio Pizuorno Machado, Sidra Naz
Journal for Immunotherapy of Cancer. 2024-11-14 - 4 citationsPilot Study to Investigate the Use of In-Clinic Sensing to Identify Optimal Stimulation Parameters for Deep Brain Stimulation Therapy in Parkinson's Disease.Sydnei Lewis, Erin Radcliffe, Steven Ojemann, Daniel R Kramer, Lisa Hirt
Neuromodulation. 2024-04-01
Journal Articles
- Phase 1 Trials of Anti-ENPP3 Antibody Drug Conjugates in Advanced Refractory Renal Cell CarcinomasRoberto Pili, John A Thompson, Clinical Cancer Research
Press Mentions
Fred Hutch Phase 1 Program Director, Dr. John Thompson, RetiresDecember 19th, 2024
Multidisciplinary Approach for Addressing Immunotherapy-Related ToxicitiesJune 28th, 2019
Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial ResultsMarch 18th, 2019- Join now to see all
Professional Memberships
- Member
- Member
- National Comprehensive Cancer NetworkMember
- Society for Immunotherapy of CancerMember
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
